As MD, expertise in the general, trauma and vascular surgery, focused in the cardiovascular field, with PhD in thrombosis,

anticoagulant drug development and clinical research. Extensive expertise acting as a bridge between the pharmaceutical company and clinical applications. Significant networking and interaction with global cardiovascular KOLs. Effectively manage teams in a broad aspect of Medical Affairs: basic to late phase research (from bench to bed-side), publications, continuous medical education and health outcomes.

Expertise in clinical development of new compounds, from early assessment, management and registration strategy (Brazilian regulatory affairs) regarding human clinical trials. Currently developing comparative studies evaluating the immunogenicity of branded and generic enoxaparin, in line with FDA requirements.

Large interaction with Pharmaceutical companies in continuous medical education linked to marketing strategies for anticoagulant drugs, including marketing MKT, medical letters, publications and conferences in main medical strategic areas updating and interacting with KOLs.

Developed over 5 of Phase IIIb and several phase III and IV programs. Leaded the Brazilian pioneer approval process of a biosimilar version of enoxaparin, following stringent and innovative regulatory rules regarding biological compounds. Since 2009 is currently available for clinical use.

Medical interaction and consulting activities with Sanofi-Aventis, Astrazeneca, Boehringer-Ingelheim since 1998, Cristlia Pharmaceuticals, Medapi Pharma and Eurofarma Laboratories since 2000. Xi-melagatran clinical trial participation, supporting its launch to the market in 2006. Close partnership for the development of Dabigatran, with Boehringer Ingelheim. Worked in the RECOVER and REMEDY trials, with active relationship with PPD, CRO in charge and KOLs.

Experience interfacing with CROs, recruiting centers and sponsors, leveling the development of IRB approvals for clinical trials, increasing enrollment in different thrombosis trials and monitoring issues.

Solid clinical background as MD, MHS, PhD and researcher in the UMICHMS/ USA.

Considerable publication background, 31 major papers published, 3 book chapters, posters and major oral presentations in international medical meetings.

Visiting professor at The Loyola University Medical Center, participating in the development of new compounds, and new target for antithrombotic/anti-platelet therapy. Experience in more than 10 international multi-center clinical trials, as well as design, investigators meetings organization, regulatory affairs, conduction of work teams, data analysis cooperation, publishing and conferences.

DETAILED PROFESSIONAL ACTIVITIES

Medical Researcher of Vascular Surgery Section from University of Michigan, AA, MI, USA (2008-2009)

Researcher of Jobst Vascular Research Laboratory (JVRL) at University of Michigan. Researcher, Surgeon and Team Coordinator of the Abdominal Aorta Aneurysm (AAA) Program on the JVRL Animal Basic Researcher, performing approximately two hundred abdominal aortic microscopy guided surgeries in mice. Outcomes evaluation included genetic and PCR analysis evaluating possible new targets for AAA pharmacological therapy. Coach the students, residents and fellows in the program of JVRL. Orientation, coordination of publications and education strategy for the research conduction. Management of budget co-responsibility in basic research

Visiting Professor and Consulting, Loyola University Medical Center, Maywood, IL (2008-present)

Reporting to the head of Thrombosis and Haemostasis department, Prof Jawed Fareed, focused on Thrombosis research and new anticoagulants development

Management of prospective phase I, II, IIIb and IV human anticoagulant trials, publications, education strategy for new anticoagulants, including evaluation of new oral anti-coagulants Mentoring medical students, residents and faculty with clinical trials and new anticoagulant compounds

Chief Executive Office - Fifty Medical Research S/S (2003-2010)

Coordination, conduction and Development of phase III and IV clinical trials in partnership with pharmaceutical companies Personal management of budget responsibilities in clinical trials Working in close partnership with Sanofi-Aventis, AstraZeneca, Boehringher Ingelheim, Eurofarma Laboratories, Cristlia Pharmaceutical and Medapi Pharma, developing original clinical trials programs and participating in international multi-center clinical trials Leading Clinical Research Teams: physicians, study nurses, monitor, pharmacologists and trainees Trials results publications Conferences and lectures regarding the researches process, methods and results Design and developing the biosimilar enoxaparin clinical trial to Eurofarma Laboratory. Leading the final approval protocols for venous thromboembolism compounds, from science to regulatory and patent protection affairs, working as the chair of steering committee of the generic enoxaparin program. This compound was approved in 2009 in Brazil and is currently available for medical use. Design, management and conduct the Antema Research to Medapi Pharma. The haemostatic product based in type I collagen was tested personally in animal model surgery and clinical human patients in the chronic wound and ulcers treatment. The results were submitted to the national regulatory agency that approved the human clinical use. Working in close partnership with Medapi Pharma, Evidence MKT, the studies were published and meetings conferences regarding the Antema were done Consultant - Marketing; Clinical Trials for Sanofi-Aventis Brazil.

Medical Investigator at Hospital e Maternidade Dr Christovo da Gama, So Paulo, Brazil (2001-2007)

Thrombosis and Haemostasis Division

Medical practice in all fields of Thrombosis and Haemostasis Medical practice in Vascular and Trauma Surgery Principal and/or co-investigator, dealing directly with patients in clinical trials IRB affairs Extensive experience as manager of clinical researches teams Extensive experience managing and reporting severe adverse events Development of research educational program to pharmaceutical doctors, nurses, physicians and technicians to hospital general employees Leading Vascular and Trauma Surgery MD Teams for research education, regulatory affairs, ethical discussions in clinical trials, comprehension of the advantages for the patients, professionals and institutions in being evolved with the Clinical Trials Enhances relationship with General Surgery and Cardiovascular MD Teams for Publications and Clinical Trials collaborative Communication of new therapeutic strategies for patients directly evolved with disease awareness campaigns as well as patients advocacy. Assistant Professor ABC School of Medicine, So Paulo, Brazil (1997-2007)

Surgical Technique and Experimental Surgery General and Trauma Surgery

Medical practice in all fields of General and Trauma Surgery Extensive experience as medical professor of general surgery fundaments for medical students. Weekly class lectures and animal model laboratory training for 10 years Experience mentoring residents in general and trauma surgery in clinical care, emergency and operation room for 10 years Mentoring and Supervising medical students and residents in researches, publications and meetings supporting their medical congress participation Creator, Coordinator, Conductor and Main Professor, of the First Formal Academic Research Program - Medical Research Fundaments - for medical students, from 2004 to 2007.

BASIC EDUCATION

PhD, Cardiovascular Surgery & Clinical Trial: 2004 - 2008, EPM-UNIFESP, SP/ Brazil Fellowship, Vascular Surgery: 2001 - 2005, Christvo da Gama Maternity and Hospital, SP/ Brazil MHS, Surgical Technique & Experimental Models: 1999 - 2001, EPM-UNIFESP, SP/ Brazil Medical Residence, Digestive Surgery: 1997 - 1999, ABC Medical School, SP/ Brazil Medical Residence, General & Trauma Surgery: 1995 - 1997, ABC Medical School, SP/ Brazil Medical Degree, MD: 1989 - 1994, ABC Medical School, SP/ Brazil

PROFESSIONAL EDUCATIONAL ACTIVITIES

Clinical Researcher & Visiting Professor: 2007 - 2011, Loyola University of Chicago, IL/ USA Clinical Researcher: 2007, Jobst Vascular Center - Toledo Hospital, OH/ USA Cardiovascular Surgery Researcher & Invited Professor: 2007 - 2010, UMICH-MS, MI/ USA

HUMAN CLINICAL TRIALS EXPERIENCE

CLEPTS (Vascular) Sanofi/Aventis: Prospective Cohort Registry Study/ Investigator/ Completed PREVAIL (Neurology) Sanofi/Aventis: Phase IV/ Investigator/ Completed EXCLAIM (Vascular) Sanofi/Aventis: Phase IV/ Investigator/ Completed; E-FLOW (Surgery) Eurofarma: Fase IIIb/ Designer and Principal Investigator/

Completed. This project included the development and final approval of a generic enoxaparin in Brazil. The drug is commercially available since September 2009.

REMEDY Dabigatran (DVT Vascular) Boehringer Ingelheim: Phase III/ PI/ Concluded RECOVER Dabigatran (DVT Vascular) Boehringer Ingelheim: Phase III/ Co-PI/ Concluded PROVIDENCE Rifalazil (Vascular) Activebiotics: Fase III - FDA Approval/ PI/ Concluded CRIS-FLOW (LMWH Generic) Eurofarma: Fase III - Sudy Designer/ PI/ Concluded TAL 0057 - Human Plasmin in PAD (Vascular) Talecris: Phase II/ Investigator/ Concluded

PHARMACEUTICAL INDUSTRY EXPERIENCE

Sanofi-Aventis: Lovenox - Consultant from 1996 to 2005. Marketing strategies nationwide, lectures, meetings and symposium organization and team trainee. Sanofi-Aventis: Lovenox - Advisory board from 2000 to 2002 Sanofi-Aventis: Lovenox - Nationwide Medical Continuous Education Program, more than hundred conferences to physicians and residents from 1996 to 2002 AstraZeneca: Ximelagatran Melagatran Marketing launch in 2006. Boehringer Ingelheim: Dabigatran (oral anti IIa) Consultant in 2007. Independent Researcher from 1994 to 2007; Multinational Pharmaceutical Industry: Medical Consultant since 1995; National Pharmaceutical Industry: Medical Consultant since 2001; Eurofarma Laboratories: National Generic Low Molecular Weight Heparin - Enoxaparin: Phase IIIb. Trial Design for the Brazilian Regulatory Agencies. The Generic Compound (Versa) was approved to the clinical use by ANVISA (Brazilian Health Regulatory Agency) 2009. Cristlia Pharmaceutical: Designed a phase IIIb trial for another generic LMWH enoxaparin. Worked with different CROs as PI and/or Investigator: PPD, Eurotrials, Intrials Assistance-Consultant from 2004 to 2006. Brazil

NATIONAL INSTITUTES OF HEALTH

Researcher and Co-investigator of Dr. Gilbert Riversu Upchurch, Vascular Surgery Professor of UMICHMS from 2008 to 2010

MEMBERSHIP

APM: Medical Paulista Association: member since 1995 CBC: Brazilian College of Surgeons: Member in 1997. Titular Member in 2005 ATLS: Assessment from 1997 to 1998: Member CBCD: Brazilian College of Digestive Surgeons: Titular Member since 2002 ISTF: International Surgical Thrombosis Forum: Senior Member since 2005 IUA/ International Union of Angiology: Member since 2008 NATF/ North American Thrombosis Forum International: Member since 2007

CORRELATED PROFESSIONAL ACTIVITIES

Brazilian Society of Angiology and Vascular Surgery: Continuous Medical Education1999-2003 - more than 200 conferences nationwide - BR) Independent Researcher: 1999 - 2003 Pharmaceutical Medical Researcher Consultant: 1999 - 2007 Chief Executive Office (CEO): Fifty Medical Research S/S: 2003 - 2011

TITLES

Visiting professor, Loyola University Medical Center, Thrombosis and Haemostasis Unit Active Member International Surgical Thrombosis Forum, in partnership with Ola Dahl, Bengk Eriksson and Michael Lassen Associated Member, Colgio Brasileiro de Cirurgies (Brazilian College of Surgeons) since1997 Associated Member, SBACV (Brazilian Society of Angiology and Vascular Surgery) since 2003 Assistant Professor, Surgical Departament of ABC Medical School since 1998

Senior Member: CBCD (Brazilian College of Digestive Surgeons) since 2002 Specialty Certified (Brazilian Board): Digestive Surgery since 2002 Senior Member: Colgio Brasileiro dos Cirurgies (Brazilian College of Surgeons) since 2002 Specialty Certified (Brazilian Board): General Surgery since 2002

PUBLICATIONS

Gomes M, Ramacciotti E, Henriques AC, et al. Generic versus branded enoxaparin in the prevention of venous thromboembolism following major abdominal surgery: report of an exploratory clinical trial. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2011; 17:6339. Gomes M, Ramacciotti E, Hoppensteadt D, et al. An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2011; 17:66-9. Ramacciotti E, Clark M, Sadeghi N, Hoppensteadt D, Thethi I, Gomes M, Fareed J. "Contaminants in Heparin: Review of the Literature, Molecular Profiling and clinical implications. Clinical and Applied Thrombosis/Hemostasis 2011; 17(2): 123-35 Cerri J, Ramacciotti E, Gomes M, Tedeschi Filho W, Piccinato CE. Latero-lateral femoro-femoral arteriovenous fistula: a new surgical approach for hemodialysis patients with no vascular access. Acta cirurgica brasileira / Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia 2011; 26: 72-6. Gomes M, Ramacciotti E, Litinas E, Fareed J. [Concerns on generic enoxaparin use in acute coronary syndrome]. Arquivos brasileiros de cardiologia 2010; 95: 551-2. M. Gomes, A. Ghosh, K. Roelofs, E. Ramacciotti, J. Futchko, O. Sadiq, P.K. Henke, J.L. Eliason, G.R. Upchurch Jr. Increased Serine Protease Activation Is Associated with AAA Formation in Males, But Not in Females, in The Elastase Induced Rodent Aneurysm Model. Journal of Surgical Research 2010; 158 Volume 158(2): 305. A. Ghosh, M. Gomes, L. Ehrlichman, E. Ramacciotti, O. Sadiq, J. Futchko, P.K. Henke, J. Eliason, G.R. Upchurch Jr.Increased Phosphorylated Extracellular Signal-Regulated

Kinase (ERK) in Abdominal Aortic Aneurysms in a Rodent Model and in Humans. Journal of Surgical Research 2010; 158(2): 217. Gomes M, Ramacciotti E, Miranda Jr F, Henriques AC, Fagundes DJ. Vascular Flow of the Gastric Fundus after Arterial De-vascularization: An Experimental Study. Journal of Surgical Research 2009; 152(1): 128-34. Dahl OE, Borris LC, Bergqvist D, Schnack Rasmussen M, Eriksson BI, Kakkar AK, Colwell CW, Caprini JA, Fletcher J, Friedman RJ, Lassen MR, Frostick SP, Sakon M, Kwong LM, Wakefield T, Ramacciotti E, Gomes M, Kakkar VV et al; International Surgical Thrombosis Forum. Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use. Int Angiol 2008; 27:60-7. Warwick D, Dahl OE, Ramacciotti E, Gomes M, Fisher WD et al. Orthopaedic thromboprophylaxis: limitations of current guidelines. J Bone Joint Surg Br 2008; 90:12732. Ramacciotti E, Gomes M. Financiamento, Autoria e Credibilidade em Pesquisa Bsica e Clnica. Vascular In 2008; Ano 3, 23: 9. Ramacciotti E, Gomes M, Tedeschi Filho W. Trombose Venosa Profunda, Cascata de Coagulao, Inflamao e Novas Drogas. Vascular In 2008; Ano 3, 24: 12-3. Ramacciotti E, Galego SJ, Gomes M, Goldenberg S, De Oliveira Gomes P, Pinto Ortiz J. Fistula size and hemodynamics: an experimental model in canine femoral arteriovenous fistulas. J Vasc Access 2007; 8(1): 33-43 (1-11). Ramacciotti E, Gomes M, de Aguiar ET, Caiafa JS, de Moura LK, Arajo GR, Truzzi A, Dietrich-Neto F; CLE-PTS Investigators. A cost analysis of the treatment of patients with post-thrombotic syndrome in Brazil. Thromb Res 2006; 118(6): 699-704. Gomes M. Antema Monography - Fascculo Especial Medapi, 2004; 2: 44p. Gomes M, Ramacciotti E. Critrios para Anlise Crtica de um Trabalho Cientfico. Atualidades Cirrgicas - Col Bras Cir SP 2004; 25: 3. Gomes M, Ramacciotti E. Tromboembolismo Venoso e Cirurgia Minimamente Invasiva. Programa de Auto-Avaliao em Cirurgia, Cirurgia Minimamente Invasiva - Col Bras Cir 2004; Ano 3 - Fascculo III - contracapa. Gomes M, Ramacciotti E. Cncer e Doena Tromboemblica. Programa de AutoAvaliao em Cirurgia, Cncer de Pulmo - Col Bras Cir 2004; Ano 3 - Fascculo II contracapa. Henriques AC, Pezzolo S, Gomes M. Out-patient VL cholecistectomy report of 70 cases. Arquivos Mdicos do ABC 2003; 27: 06-8.

Gomes M, Ramacciotti E. Profilaxia da Doena Tromboemblica no Paciente Idoso. Programa de Auto-Avaliao em Cirurgia. Paciente Idoso - Col Bras Cir 2002; Ano 2 Fascculo II, contracapa. Gomes M., Ramacciotti E. Profilaxia do Tromboembolismo Venoso em Cirurgia Geral. Programa de Auto-Avaliao em Cirurgia, Tromboembolismo Venoso - Col Bras Cir 2002; Ano 2 - Fascculo I - 20p. Gomes M, Ramacciotti E. Profilaxia da Doena Tromboemblica no Paciente Obeso Mrbido. Programa de Auto-Avaliao em Cirurgia. Paciente Obeso Mrbido - Col Bras Cir 2002; Ano 1 Fascculo II, contracapa. Gomes M, Oliveira P, Ramacciotti E. Anatomical Evaluation of the Gastric Fundus after Partial Arterial Section: Experimental Study in Dogs. Acta Cir Bras 2001; 17: 52 Henriques AC, Gomes M, Pezzolo S et al Isoperistaltic gastric tube for the complicated esophagus cancer. Rev Col Bras Cir 2001; 28: 408-13 Henriques AC, Pezzolo S, Gomes M, Godinho CA, Bazlia VAS, Speranzini MB. Intraoperative preparation of the colon. Rev Col Bras Cir 2001; 28: 271-3. Henriques AC, Pezzolo S, Gomes M, Godinho CA, Bagarollo CA. Out patient videoaparoscopic colecistectomy. Rev Col Bras Cir 2001; 28: 27-9. Henriques AC, Gomes M, Bagarollo CA. Appendex adenocarcionoma: 2 cases report. Rev Col Bras Cir 2001; 28: 393-5. Henriques AC, Horta SHC, Pezzolo S, Waisberg J, Boratto SF, Helal S, Gomes M, Speranzini MB. Local Anestesia for Selected Patients. Arq Gastroenterol 200; 158-61. Henriques AC, Pezzolo S, Godinho CA, Gomes M, Speranzini MB. Gastric tricobezoar. Arq Med ABC 2000; 23: 6-8. Henriques AC, Gomes M, Miotto MJ, Abreu E, Pezzolo S. Videolaparoscopic cholecistectomy a report of 130 cases. Arq Med ABC 1997; 1 e 2: 11-4. Henriques AC, Gomes M, Pezzolo S, Speranzini MB. The wandering Spleen. An up-to Date of the question. Arq Bras Cir Dig 1995; 10: 114-7. Henriques AC, Gomes M, Abreu E, Bento JA, Cruz RRM, Pezzolo S, Speranzini MB. Intercostal abdominal hernia. Rev Col Bras 1995; 22: 161-5 Gomes M, Henriques AC, Pezzolo S, Speranzini MB. Post-traumatic spleen pseudocyst. Rev Col Bras Cir 1995; 22: 107-10.

BOOK CHAPTERS

Gomes M, Ramacciotti E. Profilaxia do Tromboembolismo Venoso em Pacientes Cirrgicos. Doenas Vasculares Perifricas. Maffei, Lastria, Yoshida, Rollo, Giannini, Moura. 4 Ed. Editora, 2008. Ramacciotti O, Gomes M, Ramacciotti E, Faure R. Coagulopatias na Gestao. Peixoto Pr-Natal. Editora Rocca Ltda. 2003. Ramacciotti O, Gomes M, Ramacciotti E, Faure R. Vasculopatias na Gestao. Peixoto Pr-Natal. Editora Rocca Ltda. 2003

RESEARCH, CHAPTERS AND ARTICLES ON GOING

Cafer Adiguzel, Omer Iqbal, Debra Hoppensteadt, Josephine Cunanan, Eduardo Ramacciotti, Marise Gomes, Jawed Fareed. Danaparoid effect on the inhibition of microparticles generation, platelet aggregation and P-selectin expression. Loyola University Medical Center, Maywood, IL, USA. Cafer Adiguzel, Omer Iqbal, Debra Hoppensteadt, Josephine Cunanan, Eduardo Ramacciotti, Marise Gomes, Jawed Fareed. The inhibition of microparticles generation, platelet aggregation and activation by enoxaparin. Loyola University Medical Center, Maywood, IL, USA Marise Gomes, Eduardo Ramacciotti, Alexandre Cruz Henriques, Cynthia K Shortell, MD, Fausto Miranda Jr, Anti-Xa evaluation of two low-molecular heparin enoxaparins (Lovenox and generic eurofarma enoxaparin) in the prevention of venous

thromboembolism following major abdominal surgery. Fifty Medical Research/ BR, ABC School of Medicine/ BR, Duke University/ USA, UNIFESP School of Medicine/ BR. Cafer Adiguzel, Omer Iqbal, Hoppensteadt Debra, Josephine Cunanan, Eduardo Ramacciotti, Marise Gomes, Jawed Fareed. Generic versions of LMWH can be differenciated in HIT sera mediated platelet aggregation. Loyola University Medical Center, Maywood, IL, USA Jawed Fareed, Marise Gomes, Eduardo Ramacciotti, Cafer Adiguzel, Anthony

Comerota, Debra A. Hoppensteadt, Andrew Nicolaides. Contaminantes, recall process and unfractionated heparin preparations: an internal major public health problem. Loyola University Chicago IL/ USA, Jobst Vascular Center OH/ USA.

Marise Gomes, Eduardo Ramacciotti, Anthony Comerota, Cafer Adiguzel, Debra A. Hoppensteadt, Andrew Nicolaides, Jawed Fareed. An open, non-randomized,

prospective clinical trial comparing the pharmacodynamics of two enoxaparins (branded sanofi-aventis and generic biochimico/ Lovenox and Cutenox), 40mg OD, 6-14 days in healthy volunteers. Fifty Medical Research SP/ BR, Jobst Vascular Center OH/ USA, Loyola University IL/ USA. Cafer Adiguzel, Omer Iqbal, Hoppensteadt Debra, Josephine Cunanan, Eduardo Ramacciotti, Marise Gomes, Jawed Fareed. Distint batches of branded parnaparins have diferents HIT sera mediated plateled aggregation. Loyola University Medical Center, Maywood, IL, USA. Cafer Adiguzel, Omer Iqbal, Debra Hoppensteadt, Josephine Cunanan, Eduardo Ramacciotti, Marise Gomes, Jawed Fareed. Suledoxide mediated inhibition of tissue factor activation of platelet a potential mechanism for observed therapeutic effects in diabetes nephropathy. Loyola University Medical Center, Maywood, IL, USA. Gomes M, Ramacciotti E, Comerotta A, Hoppensteadt D, Fareed J. Immunogenic profile of enoxaparin and its generic Cutenox in healthy volunteers and medical ill patients. Gomes M, Ramacciotti E, Hoppensteadt, Walenga J M, Lewis B, Thethi I, Fareed J. Journal of Clinical and Applied Thrombosis and Haemostasis. Department of Pathology and Pharmacology, Cardiovascular Institute, Loyola University Medical Center,

Maywood, IL 60153, USA. Ramacciotti E, Gomes M, Hoppensteadt, Walenga JM, Lewis B, Fareed J. An Open Label, Non Randomized, Prospective Phase IV Clinical Trial Evaluating the

Imunogenicity of Branded Enoxaparin Versus Biosimilars in Healthy Volunteers. American Heart Association 2010. Department of Pathology and

Pharmacology, Cardiovascular Institute, Loyola University Medical Center, Maywood, IL 60153, USA Gomes M et al. Differential Pharmaco-equivalence of Branded and Generic Low Molecular Weight Heparins in Mediating Immunologic Responses." submitted to Clinical and Applied Thrombosis/Hemostasis, 2010.

RECENTLY ATTENDANCE EVENTS

SCIENTIFIC MEETINGS AND PRESENTATIONS

21st International Thrombosis Congress 2010 - Milan/ Italy

Pharmacodynamic Differences Between Biosimilar and Branded Enoxaparins with Reference to Their Immunogenic Profile. Gomes M, Ramacciotti E, Rao G,

Hoppensteadt D, Jeske W, Walenga J M, Fareed J Guidelines for Development of generic/ Bio-SimiLar LMWHs. Where Do We Stand? Gomes M, Ramacciotti E, Hoppensteadt D, Jeske W, Walenga J M, Litinas E, Fareed J Oversulfated Chondroitin Sulfate is not sole Contaminant in recalled Heparins. Fareed J, Ramacciotti E, Hoppensteadt D, Sadeghi N, Van Thiel D, Gomes M, George M.

North American Thrombosis Forum 2010 - Boston/ USA

VIP Thrombosis Working Group Session North American Thrombosis Summit Scientific and Clinical Discussion on Current Topics of Anticoagulation

LANGUAGES

Portuguese English